

03-30-07

DPR



Please type a plus sign (+) inside this box →

+

PTO/SB/21 (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<h2 style="text-align: center;">TRANSMITTAL FORM</h2> <p style="text-align: center;"><i>(to be used for all correspondence after initial filing)</i></p>		Application Number	10/554,043
		Filing Date	August 10, 2006
		First Named Inventor	PLAVEC, IVAN
		Group Art Unit	1631
		Examiner Name	Unassigned
Total Number of Pages in This Submission		Attorney Docket Number	SEEK-006

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Information Disclosure Statement <input checked="" type="checkbox"/> USPTO Form SB08A <input checked="" type="checkbox"/> 19 cited references <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Certified Copy of Priority Documents <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers <i>(for an Application)</i> <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s)	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group <i>(Appeal Notice, Brief, Reply Brief)</i> <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Return postcard
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Signing Attorney/Agent (Reg. No.)	PAMELA J. SHERWOOD, 36,677 BOZICEVIC, FIELD & FRANCIS, LLP
Signature	
Date	March 28, 2007

EXPRESS MAIL LABEL NO. EV 954 013 435 US

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



INFORMATION DISCLOSURE STATEMENT		Attorney Docket	SEEK-006
 Address to: Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450		First Named Inventor	PLAVEC, IVAN
		Application Number	10/554,043
		Confirmation No.	8308
		Filing Date	August 10, 2006
		Group Art Unit	1631
		Examiner Name	Unassigned
Title: "METHODS FOR CHARACTERIZING SIGNALING PATHWAYS AND COMPOUNDS THAT INTERACT THEREWITH"			

Dear Examiner:

This is an Information Disclosure Statement submitted for the Examiner's consideration. A Form PTO-SB/08A listing the references and copies of the cited foreign and non-patent literature references accompany this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record.


This Information Disclosure Statement under 37 C.F.R. §1.97 is not to be construed as a representation that: (i) a search has been made, (ii) additional information material to the examination of this application does not exist, (iii) the information, protocols, results and the like reported by third parties are accurate or enabling or (iv) any one of the above references constitutes prior art to the present application.

As applicants have not yet received a first Action on the merits, no fee is believed to be required for filing this Disclosure Statement. However, if it is determined that fees are required in connection with the filing of this document, the Commissioner is hereby authorized to charge any necessary fees, or alternatively, credit any overpayment to our Deposit Account No. 50-0815, Order No. SEEK-006.

Respectfully submitted,

BOZICEVIC, FIELD & FRANCIS LLP

By:


Pamela J. Sherwood
Registration No. 36,677

Date: March 28, 2007

BOZICEVIC, FIELD & FRANCIS LLP
1900 University Avenue, Suite 200
East Palo Alto, California 94303
Telephone: (650) 327-3400
Facsimile: (650) 327-3231



Under the Trade Secrets Protection Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/554,043
(Use as many sheets as necessary)				Filing Date	August 10, 2006
Sheet	1	of	2	First Named Inventor	PLAVEC, IVAN
				Art Unit	1631
				Examiner Name	Unassigned
				Attorney Docket Number	SEEK-006

U.S. PATENT DOCUMENTS					
Examiner Initials'	Cite No. ¹	Document Number	Publication or Filing Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ³ (if known)			
		US - 4,568,649	02-04-1986	Bertoglio-Matte	
		US - 5,569,588	10-29-1996	Ashby et al.	
		US - 5,631,153	05-20-1997	Capecchi et al.	
		US - 5,777,888	07-07-1998	Rine et al.	
		US - 5,994,076	11-30-1999	Chenchik et al.	
		US - 6,004,755	12-21-1999	Wang	
		US - 6,013,437	01-11-2000	Luria et al.	
		US - 6,148,830	11-14-2000	Friend et al.	
		US- 6,656,695 B2	12-02-2003	Berg et al.	
		US - 6,763,307	07-13-2004	Berg et al.	
		USSN 60/465,152	04-23-2003	Plavec et al.	
		USSN 10/220,999	09-11-2003	Berg et al.	
		USSN 10/236,558	09-05-2002	Plavec et al.	

FOREIGN PATENT DOCUMENTS					
Examiner Initials'	Cite No. ¹	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		WO 96/23075	08-01-1996	Boggs	
		WO 95/06132	03-02-1995	Andrianopoulos	
		WO 98/51810	11-19-1998	Olsen	
		WO 00/00600	01-06-2000	Chang	
		WO 01/67103 A1	09-13-2001	Berg et al.	
		WO 03/023573 A2	03-20-2003	Berg et al.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				<i>Complete if Known</i>	
				Application Number	10/554,043
				Filing Date	August 10, 2006
				First Named Inventor	PLAVEC, IVAN
				Art Unit	1631
				Examiner Name	Unassigned
(Use as many sheets as necessary)				Attorney Docket Number	
Sheet	2	of	2	SEEK-006	

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T ²
		ALTSCHUEL, et al., "Issues in searching molecular sequence databases," (1994) <i>Nature Genetics</i> , 6:119-129				
		BLACKSTOCK, et al., "Proteomics: Quantitative and physical mapping of cellular proteins," (1999) <i>Tibtech</i> , 17:121-127				
		COLLINS, et al., "Transcriptional regulation of endothelial cell adhesion molecules: NF-kappa B and cytokine-inducible enhancers," (1995) <i>FASEB</i> , 9:899-909				
		GIULIANI, et al., "Role of endothelial cell extracellular signal-regulated kinase1/2 in urokinase-type plasminogen activator upregulation and in vitro angiogenesis by fibroblast growth factor-2," (1999) <i>Journal of Cell Science</i> , 112 (Pt 15):2597-606				
		HATZIMANIKATIS, et al., "Proteomics: Theoretical and experimental considerations," (1999) <i>Biotechnol.</i> , 15:312-318				
		HAUSNER, et al., "The comparative growth assay: Examining the interplay of anti-cancer agents with cells carrying single gene alterations," (1999) <i>Neoplasia, Doyma</i> , 1(4):356-367				
		HELLER, et al., "Discovery and analysis of inflammatory disease-related genes using CDNA microarrays," (1997) <i>PNAS</i> , 94:2150-2155				
		KONSTANTOPOULOS, et al., "Endothelial P-selectin and VCAM-1: each can function as primary adhesive mechanisms for T cells under conditions of flow," (1997) <i>J of Leukocyte Biology</i> , 61:179-187				
		MAY, et al., "Effects of protein tyrosine kinase inhibitors on cytokine-induced adhesion molecule expression by human umbilical vein endothelial cells," (1996) <i>British Journal of Pharmacology</i> , 118(7):1761-1771				
		MULLNER, et al., "Proteomics: A new way for drug target discovery," (1998) <i>Arzneim-Forsch</i> , 48(1):93-95				
		NELLEN, et al., "What makes an mRNA anti-sense-itive?," (1993) <i>TIBS</i> , 18:419-423				
		RICE, et al., "Development of a high volume screen to identify inhibitors of endothelial cell activation," (1996) <i>Anal Biochemistry</i> , 241:254-259				
		SHINKAI, et al., "A novel human CC chemokine, eotaxin-3, which is expressed in IL-4-stimulated vascular endothelial cells, exhibits potent activity eosinophils," (1999) <i>J of Immunology</i> , 163:1602-1610				

Examiner Signature		Date Considered
--------------------	--	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.